Diff	BMA	TION DISCLOSURE NTATION	RDID 01034CIP US			10/669,831						
MAY 2"	(Lise ser	and sheets if necessary)	Applicants(s) Sigler et al.									
MAY 2 3 2005 C			Filing Date September 24, 2003 Group An Unit 1641									
U.S. PATENT DOCUMENTS												
ExeliPAI	Document Number		Date	Name	Class	Subclass	Filing Date (If Appropriate)					
		U S 2003/010088 A1	5/29/2003	Sigler et al.	C12N	9/99						
					-							
						<u> </u>						
						 						
		<u> </u>				<u> </u>						
						1						
	l		FOREIGN PAT	TENT DOCUMENTS		<u> </u>						
	Ref	Document Number	Date	Country	Class	Subclass	Translation					
MEC		WO 03/075010 A2	9/12/2003	PCT	G01N	33/532	Abstract					
		· · · · · · · · · · · · · · · · · · ·										
Examiner Mary E. Ceperlay Date Considered 04/18/06												
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not												
considered. Include copy of this form with next communication to applicant. FORM PTO-A820 P09A/REV04 Sheet 1 of 1												

INFORMATION DISCLOSURE CITATION				Docket Number (Optional) RDID 01034CIP US			Application Number 10/669,831				
(Use several sheets if necessary)				Applicants(s) Sigler et al.				-			
				September	24, 2003		Group Art Unit 160	roup Art Unit 164			
U.S. PATENT DOCUMENTS											
Examiner Initials	Ref	Document Number	Date		Name	Class	Subclass	Filing Date (If Appropriate)			
	10	- E									
		17700 6									
	Kr	le le									
	THE STATE OF THE S										
		MADERALIT									
						ļ		·			
					·						
	ļ					<u> </u>					
								1			
	 										
						ļ					
	ļ										
			,								
			•			 					
	1		FORI	EIGN PATENT	DOCUMENTS	L		1			
	Ref	Document Number	Date		Country	Class	Subclass	Translation			
me		FR 2773994	7/30/99	France		ļ					
MC	 -	EP 1207394	5/22/02	EP, JP		ļ	-				
I	<u> </u>										
		Other D	Ocuments (Inc	luding Author	Title Data Borin	ent Page	Btc.)	L			
					Title, Date, Pertin			nged			
Valdez et al. "Response to immunization with recall and neoantigens after administration of an HIV-1 protease inhibitor-containing regimen." AIDS 1-21 Wiltshire et al. "Chromatographic and Immunochemical Approaches to the Protease Inhibitor Saquinavir in Plasma". Analytical Biochemistry 2000, 28 Akeb et al. "Quantification of plasma and intracellular levels of the HIV protease inhibitor Saquinavir by competitive FLISA". Journal of Immunological Methods 263.											
you		1-21									
2.00		Wiltshire et al. "Chromatographic and Immunochemical Approaches to the Analysis of the HIV									
MEC		Protease Inhibitor S									
11/4/											
W(C	Akeb et al. "Quantification of plasma and intracellular levels of the HIV protease in ritonavir by competitive ELISA". Journal of Immunological Methods 263 (2002) 1-										
Examiner Mary E. Ceperley Date Considered 04/18/06											
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not											
considered. Include copy of this form with next communication to applicant.											